Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Definium Therapeutics

38.50
-1.2200-3.07%
Pre-market: 37.27-1.2300-3.19%05:32 EDT
Volume:1.57M
Turnover:60.96M
Market Cap:5.17B
PE:-11.06
High:40.00
Open:39.38
Low:38.15
Close:39.72
52wk High:49.70
52wk Low:8.70
Shares:134.37M
Float Shares:131.11M
Volume Ratio:0.90
T/O Rate:1.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4823
EPS(LYR):-2.0600
ROE:-64.09%
ROA:-20.64%
PB:5.63
PE(LYR):-18.69

Loading ...

OverviewCompanyNewsFilings

Top Midday Stories: Consumer Prices Rise 3.4% YoY in July; CoreWeave Q2 Loss Narrower Than Expectations

MT Newswires Live
·
Aug 12

Ami Fadia Reiterates Buy on Definium (DFTX) as Strong Phase 3 VOYAGE Data Support Unchanged $50 Price Target

TIPRANKS
·
Aug 12

Exchange-Traded Funds, Equity Futures Gain Pre-Bell Wednesday Amid In-Line Consumer Inflation Data, Tech Gains

MT Newswires Live
·
Aug 12

Definium Therapeutics Posts Phase 3 Voyage Topline Results Presentation

Reuters
·
Aug 12

Definium Therapeutics Shares Jump 22% Premarket After Co's Anxiety Disorder Drug Meets Late-Stage Trial Goal

THOMSON REUTERS
·
Aug 12

Definium Says DT120 Phase 3 GAD Study Shows 5.4-Point HAM-A Benefit vs Placebo

MT Newswires Live
·
Aug 12

Definium Therapeutics Says Anxiety Treatment Met Primary Endpoint in Late-Stage Trial

Dow Jones
·
Aug 12

Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 Odt in Generalized Anxiety Disorder

THOMSON REUTERS
·
Aug 12

Definium Therapeutics: Phase 3 Voyage Study of DT120 Odt Met Primary & Key Secondary Efficacy Endpoints

THOMSON REUTERS
·
Aug 12

Definium Therapeutics: Participants on DT120 Odt Achieved Statistically Significant Reduction in Hamilton Anxiety Rating Scale Score

THOMSON REUTERS
·
Aug 12

Definium Says LSD-Based Pill Reduces Anxiety in Late-Stage Study

Reuters
·
Aug 12

Definium Therapeutics: DT120 Odt Generally Well Tolerated in Study, no New Safety Signals Including no Suicidality Signal

THOMSON REUTERS
·
Aug 12

NASDAQ Trade Halt Halt News Pending at 06:55 Am

Reuters
·
Aug 12

Evercore ISI Sticks to Its Buy Rating for Definium Therapeutics (DFTX)

TIPRANKS
·
Aug 10

Definium Therapeutics (DFTX) Is Up 6.0% After Strong DT120 Data Amid Wider Q2 Net Loss

Simply Wall St.
·
Aug 09

Definium Therapeutics: Buy Rating Reiterated on Strong Clinical and Financial Positioning; $74 Price Target Maintained

TIPRANKS
·
Aug 08

Definium Therapeutics (DFTX) Gets a Buy from Jefferies

TIPRANKS
·
Aug 08

Definium Therapeutics Price Target Raised to $75.00/Share from $73.00 by Piper Sandler

Dow Jones
·
Aug 08

Ami Fadia Reiterates Buy on Definium Therapeutics, Keeps $50 Price Target Ahead of Key GAD Phase 3 Readouts

TIPRANKS
·
Aug 07

Definium Therapeutics Posts Strong Phase 3 Data and Capital Raise to Fund Psychedelic Pipeline

TIPRANKS
·
Aug 07
More